Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fudan Univ. ANXA3 compound 18a5
- Development stage
- Preclinical
- Lead developer
- Fudan University
01
Overview
Fudan Univ. ANXA3 compound 18a5: sourced facts only. name: "Collectively, 18a5 proved to be a promising lead compound to treat TNBC through the degradation of ANXA3." [PMID:40013713]; target: "Collectively, 18a5 proved to be a promising lead compound to treat TNBC through the degradation of ANXA3." [PMID:40013713]; developer: "School of Pharmacy, Fudan University, 826 Zhangheng Road, Shanghai 201203, China." [PMID:40013713]; stage: "In particular, 18a5 showed more desirable ANXA3 selective degradation than (R)-SL18 and displayed excellent inhibitory effect in a TNBC tumor xenograft model (TGI = 96%)." [PMID:40013713]
02
Targets
ANXA3
Beyond the preview
Go deeper on Fudan Univ. ANXA3 compound 18a5.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fudan Univ. ANXA3 compound 18a5.